Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Basel, Switzerland.
Ann Neurol. 2024 May;95(5):886-897. doi: 10.1002/ana.26886. Epub 2024 Feb 16.
Uncertainty remains regarding antithrombotic treatment in cervical artery dissection. This analysis aimed to explore whether certain patient profiles influence the effects of different types of antithrombotic treatment.
This was a post hoc exploratory analysis based on the per-protocol dataset from TREAT-CAD (NCT02046460), a randomized controlled trial comparing aspirin to anticoagulation in patients with cervical artery dissection. We explored the potential effects of distinct patient profiles on outcomes in participants treated with either aspirin or anticoagulation. Profiles included (1) presenting with ischemia (no/yes), (2) occlusion of the dissected artery (no/yes), (3) early versus delayed treatment start (</>median), and (4) intracranial extension of the dissection (no/yes). Outcomes included clinical (stroke, major hemorrhage, death) and magnetic resonance imaging outcomes (new ischemic or hemorrhagic brain lesions) and were assessed for each subgroup in separate logistic models without adjustment for multiple testing.
All 173 (100%) per-protocol participants were eligible for the analyses. Participants without occlusion had decreased odds of events when treated with anticoagulation (odds ratio [OR] = 0.28, 95% confidence interval [CI] = 0.07-0.86). This effect was more pronounced in participants presenting with cerebral ischemia (n = 118; OR = 0.16, 95% CI = 0.04-0.55). In the latter, those with early treatment (OR = 0.26, 95% CI = 0.07-0.85) or without intracranial extension of the dissection (OR = 0.34, 95% CI = 0.11-0.97) had decreased odds of events when treated with anticoagulation.
Anticoagulation might be preferable in patients with cervical artery dissection presenting with ischemia and no occlusion or no intracranial extension of the dissection. These findings need confirmation. ANN NEUROL 2024;95:886-897.
在颈内动脉夹层中,抗血栓治疗仍存在不确定性。本分析旨在探讨特定患者特征是否会影响不同类型抗血栓治疗的效果。
这是基于 TREAT-CAD(NCT02046460)的事后探索性分析,该随机对照试验比较了阿司匹林和抗凝治疗颈内动脉夹层患者的效果。我们探讨了不同患者特征对接受阿司匹林或抗凝治疗的参与者结局的潜在影响。特征包括(1)出现缺血(无/有),(2)夹层动脉闭塞(无/有),(3)早期与延迟治疗开始(</>中位数),和(4)夹层颅内延伸(无/有)。结局包括临床(卒 中、大出血、死亡)和磁共振成像结局(新发缺血或出血性脑病变),并在不进行多重检验调整的情况下,分别在单独的逻辑模型中对每个亚组进行评估。
所有 173 名(100%)按方案参与者均符合分析条件。无夹层闭塞的参与者接受抗凝治疗时,事件发生的可能性降低(比值比 [OR] = 0.28,95%置信区间 [CI] = 0.07-0.86)。在出现脑缺血的参与者中(n = 118;OR = 0.16,95%CI = 0.04-0.55),这种效果更为明显。在后者中,早期治疗(OR = 0.26,95%CI = 0.07-0.85)或无夹层颅内延伸(OR = 0.34,95%CI = 0.11-0.97)的参与者接受抗凝治疗时,事件发生的可能性降低。
对于出现缺血且无夹层闭塞或无夹层颅内延伸的颈内动脉夹层患者,抗凝可能是更好的选择。这些发现需要进一步证实。